Minakem Generic APIs Minakem Generic APIs

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of SHINE Technologies.

    Client Virtual Booth

    SHINE TECHNOLOGIES

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    SHINE Technologies
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    3400 Innovation Ct. Janesville, WI 53546
    Telephone
    Telephone
    +1 6082101060
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.shinefusion.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/shinefusion/
    Twitter
    Twitter
    https://twitter.com/shinefusion

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Telix and SHINE Partner for Lutetium-177 Supply

    Details:

    SHINE will immediately commence supply of n.c.a. 177Lu for use in clinical trials of Telix’s therapeutic candidates TLX591 (177Lu-rosopatamab for advanced prostate cancer) and TLX250 (177Lu-girentuximab for kidney cancer), with particular focus on the U.S. market.


    Lead Product(s): 177Lu-rosopatamab

    Therapeutic Area: Oncology Product Name: TLX591

    Highest Development Status: Phase IIIProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Telix Pharmaceuticals

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Agreement February 11, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Shine Closes $80-Million Series C Financing Supported by Fidelity Management and Research Company Llc

    Details:

    Fuding will support SHINE's continued effort to make strong progress in their work to commercialize molybdenum-99, an essential diagnostic isotope, and lutetium-177, a therapeutic isotope that is showing great promise for the treatment of cancer.


    Lead Product(s): Lutetium-177

    Therapeutic Area: Oncology Product Name: Undisclosed

    Highest Development Status: UndisclosedProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Fidelity Management and Research Company LLC

    Deal Size: $80.0 million Upfront Cash: Undisclosed

    Deal Type: Series C Financing September 02, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    bora-pharmaceuticals-2024-07-01

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search